Last reviewed · How we verify

DTPw-HBV/Hib Kft vaccine GSK323527A

GlaxoSmithKline · Phase 3 active Biologic

DTPw-HBV/Hib Kft vaccine GSK323527A is a Combination vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Active immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and young children.

This combination vaccine stimulates immune responses against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b through inactivated antigens and recombinant proteins.

This combination vaccine stimulates immune responses against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b through inactivated antigens and recombinant proteins. Used for Active immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and young children.

At a glance

Generic nameDTPw-HBV/Hib Kft vaccine GSK323527A
SponsorGlaxoSmithKline
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhasePhase 3

Mechanism of action

DTPw-HBV/Hib is a pentavalent vaccine combining whole-cell pertussis (DTPw), hepatitis B surface antigen (HBV), and Haemophilus influenzae type b conjugate (Hib) components. It primes both humoral and cellular immunity by presenting multiple pathogen-derived antigens to the immune system, generating protective antibodies and T-cell responses against these five infectious diseases. The vaccine is administered in infancy to establish immunological memory before natural exposure to these pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTPw-HBV/Hib Kft vaccine GSK323527A

What is DTPw-HBV/Hib Kft vaccine GSK323527A?

DTPw-HBV/Hib Kft vaccine GSK323527A is a Combination vaccine drug developed by GlaxoSmithKline, indicated for Active immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and young children.

How does DTPw-HBV/Hib Kft vaccine GSK323527A work?

This combination vaccine stimulates immune responses against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b through inactivated antigens and recombinant proteins.

What is DTPw-HBV/Hib Kft vaccine GSK323527A used for?

DTPw-HBV/Hib Kft vaccine GSK323527A is indicated for Active immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and young children.

Who makes DTPw-HBV/Hib Kft vaccine GSK323527A?

DTPw-HBV/Hib Kft vaccine GSK323527A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is DTPw-HBV/Hib Kft vaccine GSK323527A in?

DTPw-HBV/Hib Kft vaccine GSK323527A belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is DTPw-HBV/Hib Kft vaccine GSK323527A in?

DTPw-HBV/Hib Kft vaccine GSK323527A is in Phase 3.

What are the side effects of DTPw-HBV/Hib Kft vaccine GSK323527A?

Common side effects of DTPw-HBV/Hib Kft vaccine GSK323527A include Injection site reactions (pain, redness, swelling), Fever, Irritability, Drowsiness, Loss of appetite.

Related